{"id":551,"date":"2026-02-28T11:52:45","date_gmt":"2026-02-28T11:52:45","guid":{"rendered":"https:\/\/heartcareforyou.in\/blog\/hypercholesterolemia-definition-clinical-context-and-cardiology-overview\/"},"modified":"2026-02-28T11:52:45","modified_gmt":"2026-02-28T11:52:45","slug":"hypercholesterolemia-definition-clinical-context-and-cardiology-overview","status":"publish","type":"post","link":"https:\/\/heartcareforyou.in\/blog\/hypercholesterolemia-definition-clinical-context-and-cardiology-overview\/","title":{"rendered":"Hypercholesterolemia: Definition, Clinical Context, and Cardiology Overview"},"content":{"rendered":"\n<h2 class=\"wp-block-heading\">Hypercholesterolemia Introduction (What it is)<\/h2>\n\n\n\n<p>Hypercholesterolemia means a higher-than-desired level of cholesterol in the blood.<br\/>\nIt is a medical condition and a cardiovascular risk factor rather than a symptom.<br\/>\nIt is commonly identified on a lipid panel ordered in primary care and cardiology.<br\/>\nIn cardiology, it is closely linked to atherosclerotic cardiovascular disease risk assessment and prevention.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Why Hypercholesterolemia matters in cardiology (Clinical relevance)<\/h2>\n\n\n\n<p>Hypercholesterolemia matters because cholesterol-containing lipoproteins contribute to atherosclerosis, the underlying process behind many heart and vascular conditions. In clinical cardiology, long-term exposure to elevated atherogenic lipoproteins\u2014especially low-density lipoprotein (LDL) particles\u2014is associated with higher risk of coronary artery disease, ischemic stroke, and peripheral artery disease.<\/p>\n\n\n\n<p>For learners, Hypercholesterolemia is a foundational concept because it connects biochemistry (lipoproteins), vascular biology (endothelial function and plaque formation), and clinical decision-making (risk stratification and prevention strategies). It also illustrates how cardiology often focuses on modifying long-term risk, not only treating acute events.<\/p>\n\n\n\n<p>In practice, identifying Hypercholesterolemia can clarify why a patient developed premature atherosclerotic cardiovascular disease, help estimate future risk, and inform the intensity of preventive strategies. It also prompts clinicians to look for secondary causes (such as hypothyroidism or certain medications) and inherited disorders (such as familial hypercholesterolemia), where early recognition can change lifetime risk trajectories.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Classification \/ types \/ variants<\/h2>\n\n\n\n<p>Hypercholesterolemia is commonly categorized by cause and by the predominant lipid abnormality. These categories help clinicians frame differential diagnosis and choose an evaluation strategy.<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Primary (genetic) Hypercholesterolemia<\/strong><\/li>\n<li>Caused mainly by inherited variants affecting lipoprotein production or clearance.<\/li>\n<li><strong>Familial hypercholesterolemia (FH)<\/strong> is a key subtype, often related to impaired LDL clearance (for example, due to LDL receptor pathway dysfunction).<\/li>\n<li>\n<p>May present with very high LDL levels, early atherosclerotic disease, or a family history of premature cardiovascular events.<\/p>\n<\/li>\n<li>\n<p><strong>Secondary (acquired) Hypercholesterolemia<\/strong><\/p>\n<\/li>\n<li>Cholesterol elevation resulting from another condition or exposure.<\/li>\n<li>\n<p>Examples of contributors include hypothyroidism, nephrotic syndrome, cholestatic liver disease, chronic kidney disease, dietary patterns, and some medications (the exact relationship varies by drug and patient factors).<\/p>\n<\/li>\n<li>\n<p><strong>Isolated Hypercholesterolemia vs mixed dyslipidemia<\/strong><\/p>\n<\/li>\n<li><strong>Isolated<\/strong>: predominant elevation of LDL cholesterol (LDL-C).<\/li>\n<li>\n<p><strong>Mixed<\/strong>: LDL elevation with elevated triglycerides and\/or low high-density lipoprotein cholesterol (HDL-C), often seen with insulin resistance and metabolic syndrome.<\/p>\n<\/li>\n<li>\n<p><strong>Phenotypic patterns sometimes discussed in education<\/strong><\/p>\n<\/li>\n<li>Patterns based on which lipoproteins are elevated (for example, LDL-predominant vs remnant-rich profiles). Terminology varies by clinician and case, and by local protocol.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\">Relevant anatomy &amp; physiology<\/h2>\n\n\n\n<p>Hypercholesterolemia affects cardiovascular health primarily through the arterial system rather than directly altering heart chambers or valves. The key \u201canatomy\u201d is the vascular wall\u2014especially the intima of medium and large arteries.<\/p>\n\n\n\n<p>High-level physiology concepts that connect cholesterol to cardiology include:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Coronary circulation<\/strong><\/li>\n<li>The coronary arteries supply oxygenated blood to the myocardium.<\/li>\n<li>\n<p>Atherosclerotic plaque in coronary arteries can reduce blood flow (stable ischemia) or rupture and thrombose (acute coronary syndrome).<\/p>\n<\/li>\n<li>\n<p><strong>Cerebrovascular and peripheral arterial circulation<\/strong><\/p>\n<\/li>\n<li>\n<p>Similar plaque processes occur in carotid, cerebral, renal, and lower-extremity arteries, contributing to stroke and peripheral artery disease.<\/p>\n<\/li>\n<li>\n<p><strong>Lipoprotein transport<\/strong><\/p>\n<\/li>\n<li>Cholesterol is transported in the blood within lipoproteins.<\/li>\n<li><strong>LDL<\/strong> is a major carrier of cholesterol to peripheral tissues and is strongly associated with atherosclerosis when present in excess.<\/li>\n<li>\n<p><strong>HDL<\/strong> participates in reverse cholesterol transport, though HDL-C level alone does not fully capture HDL function.<\/p>\n<\/li>\n<li>\n<p><strong>Endothelial function<\/strong><\/p>\n<\/li>\n<li>The endothelium regulates vascular tone, inflammation, and thrombosis.<\/li>\n<li>Atherogenic lipoproteins can promote endothelial dysfunction, which is an early step in atherosclerosis.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\">Pathophysiology or mechanism<\/h2>\n\n\n\n<p>The central mechanism linking Hypercholesterolemia to cardiovascular disease is <strong>atherogenesis<\/strong>, a chronic inflammatory process within the arterial wall.<\/p>\n\n\n\n<p>A simplified, stepwise framework:<\/p>\n\n\n\n<ol class=\"wp-block-list\">\n<li>\n<p><strong>Atherogenic particle burden and retention<\/strong>\n   &#8211; LDL and other apolipoprotein B (apoB)-containing particles circulate in blood.\n   &#8211; Excess apoB-containing particles can penetrate and become retained in the arterial intima, particularly at sites of disturbed flow (branch points and curvatures).<\/p>\n<\/li>\n<li>\n<p><strong>Modification and inflammatory signaling<\/strong>\n   &#8211; Retained lipoproteins can undergo oxidative and other modifications.\n   &#8211; The endothelium expresses adhesion molecules and chemokines, recruiting monocytes and other inflammatory cells.<\/p>\n<\/li>\n<li>\n<p><strong>Foam cell formation<\/strong>\n   &#8211; Monocytes become macrophages and ingest modified lipoproteins.\n   &#8211; Lipid-laden macrophages (\u201cfoam cells\u201d) accumulate, forming early fatty streaks.<\/p>\n<\/li>\n<li>\n<p><strong>Plaque growth and remodeling<\/strong>\n   &#8211; Smooth muscle cells migrate and proliferate, contributing to a fibrous cap.\n   &#8211; The plaque can enlarge over time, narrowing the lumen or remodeling outward.<\/p>\n<\/li>\n<li>\n<p><strong>Plaque instability and thrombosis<\/strong>\n   &#8211; In some plaques, inflammation and proteolytic activity can weaken the fibrous cap.\n   &#8211; Cap rupture or erosion exposes thrombogenic material, leading to clot formation and acute ischemic events.<\/p>\n<\/li>\n<\/ol>\n\n\n\n<p>Not all atherosclerotic risk is explained by LDL alone. Other factors\u2014blood pressure, smoking, diabetes, inflammation, lipoprotein(a), and genetics\u2014modify risk. The relative contribution of each factor varies by patient and clinical context.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Clinical presentation or indications<\/h2>\n\n\n\n<p>Hypercholesterolemia itself is usually <strong>asymptomatic<\/strong> and is most often found through screening or evaluation of cardiovascular risk. Typical clinical scenarios include:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>An incidental elevated cholesterol level on routine blood work.<\/li>\n<li>Risk assessment in a patient with hypertension, diabetes, chronic kidney disease, or smoking history.<\/li>\n<li>Evaluation after an atherosclerotic event (for example, myocardial infarction or ischemic stroke) to guide secondary prevention planning.<\/li>\n<li>Assessment of <strong>premature<\/strong> coronary artery disease or strong family history of early cardiovascular events.<\/li>\n<li>Physical findings that may raise suspicion of a genetic lipid disorder (more typical in familial hypercholesterolemia):<\/li>\n<li>Tendon xanthomas<\/li>\n<li>Xanthelasma (cholesterol deposits on eyelids)<\/li>\n<li>Corneal arcus (particularly when seen at a young age)<\/li>\n<li>Workup of suspected secondary contributors (for example, abnormal thyroid studies alongside lipid abnormalities).<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\">Diagnostic evaluation &amp; interpretation<\/h2>\n\n\n\n<p>Evaluation focuses on confirming the lipid abnormality, characterizing the lipoprotein pattern, and assessing overall cardiovascular risk. Specific protocols vary by clinician and patient factors.<\/p>\n\n\n\n<p>Common components include:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>History<\/strong><\/li>\n<li>Personal history of coronary artery disease, stroke, or peripheral artery disease.<\/li>\n<li>Family history of premature cardiovascular disease and known lipid disorders.<\/li>\n<li>Diet pattern, physical activity, alcohol intake, and tobacco exposure.<\/li>\n<li>Medication review (some agents can worsen lipid profiles).<\/li>\n<li>\n<p>Conditions associated with secondary dyslipidemia (for example, hypothyroidism, kidney disease).<\/p>\n<\/li>\n<li>\n<p><strong>Physical examination<\/strong><\/p>\n<\/li>\n<li>Blood pressure, body habitus, and signs of insulin resistance.<\/li>\n<li>Targeted inspection for xanthomas, xanthelasma, and corneal arcus when clinically relevant.<\/li>\n<li>\n<p>Vascular exam when symptoms suggest established atherosclerosis.<\/p>\n<\/li>\n<li>\n<p><strong>Laboratory testing<\/strong><\/p>\n<\/li>\n<li><strong>Lipid panel<\/strong> reporting total cholesterol, LDL-C, HDL-C, and triglycerides.<ul>\n<li>Many settings accept non-fasting sampling, though interpretation can vary with triglyceride levels and local practice.<\/li>\n<\/ul>\n<\/li>\n<li><strong>Non-HDL cholesterol<\/strong> (total cholesterol minus HDL-C) is sometimes used as a practical measure of atherogenic cholesterol burden.<\/li>\n<li><strong>Apolipoprotein B (apoB)<\/strong> may be used to estimate the number of atherogenic particles, particularly when triglycerides are elevated.<\/li>\n<li><strong>Lipoprotein(a) [Lp(a)]<\/strong> may be checked as an inherited risk enhancer in selected patients; testing patterns vary by protocol.<\/li>\n<li>\n<p>Tests for secondary causes as indicated (for example, thyroid-stimulating hormone, liver enzymes, kidney function, glucose or hemoglobin A1c).<\/p>\n<\/li>\n<li>\n<p><strong>Assessment for familial hypercholesterolemia (FH)<\/strong><\/p>\n<\/li>\n<li>Considered when LDL levels are markedly elevated, when there is premature atherosclerotic disease, or when family history is suggestive.<\/li>\n<li>\n<p>Some clinicians use clinical scoring systems and may consider genetic testing; approaches vary by region and availability.<\/p>\n<\/li>\n<li>\n<p><strong>Cardiovascular risk interpretation<\/strong><\/p>\n<\/li>\n<li>Lipids are interpreted in the context of overall risk (age, blood pressure, diabetes status, smoking, and prior atherosclerotic disease).<\/li>\n<li>Risk estimation tools may be used to guide intensity of prevention strategies; the choice of tool varies by practice setting.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\">Management overview (General approach)<\/h2>\n\n\n\n<p>Management aims to reduce atherosclerotic risk by lowering atherogenic lipoprotein burden and addressing coexisting risk factors. The exact plan varies by clinician and case.<\/p>\n\n\n\n<p>Broad components include:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Lifestyle and risk-factor foundations<\/strong><\/li>\n<li>Nutrition patterns that reduce atherogenic lipoproteins (for example, reducing saturated fat and emphasizing fiber-rich foods) are commonly discussed in preventive cardiology.<\/li>\n<li>Regular physical activity supports cardiometabolic health and can improve lipid patterns in some patients.<\/li>\n<li>Weight management strategies may help in mixed dyslipidemia associated with insulin resistance.<\/li>\n<li>\n<p>Tobacco cessation and blood pressure control are critical because they strongly modify vascular risk independent of cholesterol.<\/p>\n<\/li>\n<li>\n<p><strong>Medication-based lipid lowering (medical therapy)<\/strong><\/p>\n<\/li>\n<li><strong>Statins<\/strong> reduce hepatic cholesterol synthesis and upregulate LDL receptor activity, lowering LDL-C and reducing atherosclerotic risk in many populations.<\/li>\n<li><strong>Ezetimibe<\/strong> reduces intestinal cholesterol absorption and is often used when additional LDL lowering is needed or when statin intolerance is a concern.<\/li>\n<li><strong>PCSK9 inhibitors<\/strong> (proprotein convertase subtilisin\/kexin type 9 inhibitors) increase LDL receptor recycling, substantially lowering LDL-C in selected patients.<\/li>\n<li><strong>Bempedoic acid<\/strong> lowers cholesterol synthesis upstream of the statin target and may be considered in specific scenarios.<\/li>\n<li><strong>Bile acid sequestrants<\/strong> can lower LDL-C in some patients but may be limited by gastrointestinal effects and triglyceride considerations.<\/li>\n<li>\n<p>In <strong>mixed dyslipidemia<\/strong>, therapies targeting triglyceride-rich lipoproteins may be considered depending on the clinical scenario; the choice depends on the overall risk profile and comorbidities.<\/p>\n<\/li>\n<li>\n<p><strong>Management in higher-risk contexts<\/strong><\/p>\n<\/li>\n<li>In <strong>secondary prevention<\/strong> (patients with established atherosclerotic cardiovascular disease), lipid-lowering intensity is often greater than in primary prevention; exact targets and algorithms vary by guideline and clinician.<\/li>\n<li>\n<p>In <strong>familial hypercholesterolemia<\/strong>, early recognition and sustained LDL reduction are typically emphasized due to lifelong exposure; family screening discussions may be relevant.<\/p>\n<\/li>\n<li>\n<p><strong>Procedural or advanced options (selected cases)<\/strong><\/p>\n<\/li>\n<li><strong>Lipoprotein apheresis<\/strong> is used in specific, uncommon situations (for example, severe inherited hypercholesterolemia with inadequate response to standard therapy). Availability and indications vary by region and protocol.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\">Complications, risks, or limitations<\/h2>\n\n\n\n<p>Hypercholesterolemia is primarily a risk factor for longer-term vascular disease rather than a condition that causes immediate symptoms. Important complications and limitations to understand include:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Atherosclerotic cardiovascular disease outcomes<\/strong><\/li>\n<li>Coronary artery disease (stable angina, myocardial infarction)<\/li>\n<li>Ischemic stroke and transient ischemic attack<\/li>\n<li>Peripheral artery disease (claudication, limb ischemia)<\/li>\n<li>\n<p>Aortic atherosclerosis and aneurysmal disease risk can be influenced by multiple factors; attribution varies by patient context.<\/p>\n<\/li>\n<li>\n<p><strong>Familial hypercholesterolemia-associated risks<\/strong><\/p>\n<\/li>\n<li>Earlier and more aggressive atherosclerosis due to prolonged exposure to high LDL particle burden.<\/li>\n<li>\n<p>Under-recognition can delay risk reduction; detection depends on clinical suspicion and screening practices.<\/p>\n<\/li>\n<li>\n<p><strong>Limitations of lipid measurements<\/strong><\/p>\n<\/li>\n<li>Day-to-day biologic variability and effects of recent illness can alter lipid levels.<\/li>\n<li>Calculated LDL-C can be less reliable when triglycerides are high; alternative measures (non-HDL-C or apoB) may be considered depending on protocol.<\/li>\n<li>\n<p>HDL-C level does not necessarily reflect HDL function, and \u201cnormal\u201d values do not eliminate risk from other factors.<\/p>\n<\/li>\n<li>\n<p><strong>Risks or downsides related to management (general)<\/strong><\/p>\n<\/li>\n<li>Lifestyle change implementation can be limited by access, culture, time, and comorbidities.<\/li>\n<li>Medication tolerability and adherence vary by patient.<\/li>\n<li>Drug\u2013drug interactions and side effects are therapy-specific and require individualized clinical oversight.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\">Prognosis &amp; follow-up considerations<\/h2>\n\n\n\n<p>Prognosis depends less on a single cholesterol value and more on <strong>cumulative exposure<\/strong> to atherogenic lipoproteins over time, combined with other risk factors (blood pressure, diabetes, smoking, kidney disease, and family history). Hypercholesterolemia identified early\u2014particularly when it reflects an inherited disorder\u2014often represents a longer duration of exposure, which can translate to higher lifetime risk if unaddressed.<\/p>\n\n\n\n<p>Follow-up typically focuses on:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Reassessing lipid levels over time<\/strong><\/li>\n<li>To evaluate response and adherence and to confirm that results are stable rather than transient.<\/li>\n<li>\n<p>Frequency and specific testing choices vary by clinician and patient factors.<\/p>\n<\/li>\n<li>\n<p><strong>Monitoring overall cardiovascular risk<\/strong><\/p>\n<\/li>\n<li>\n<p>Blood pressure, glycemic status, kidney function, and lifestyle factors can meaningfully shift risk even if cholesterol improves.<\/p>\n<\/li>\n<li>\n<p><strong>Checking for secondary causes when patterns change<\/strong><\/p>\n<\/li>\n<li>\n<p>A sudden rise in LDL-C or triglycerides may prompt evaluation for new medications, endocrine disorders, or systemic illness.<\/p>\n<\/li>\n<li>\n<p><strong>Long-term prevention framing<\/strong><\/p>\n<\/li>\n<li>For many patients, Hypercholesterolemia is managed as a chronic risk condition, similar to hypertension, with periodic reassessment and adjustment based on changing risk and tolerability.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\">Hypercholesterolemia Common questions (FAQ)<\/h2>\n\n\n\n<p><strong>Q: What does Hypercholesterolemia actually mean in plain language?<\/strong><br\/>\nIt means there is more cholesterol in the bloodstream than is considered desirable for long-term vascular health. Clinically, the focus is usually on LDL-related cholesterol because it is closely tied to atherosclerosis. It is generally detected on a blood test rather than by symptoms.<\/p>\n\n\n\n<p><strong>Q: Is Hypercholesterolemia a disease or a lab finding?<\/strong><br\/>\nIt is a medical condition defined by persistently elevated cholesterol levels, identified through laboratory testing. It can exist on its own or as part of a broader metabolic pattern (for example, mixed dyslipidemia). Clinicians treat it as a modifiable cardiovascular risk factor.<\/p>\n\n\n\n<p><strong>Q: Can you feel high cholesterol?<\/strong><br\/>\nMost people do not have symptoms directly caused by elevated cholesterol. Symptoms typically arise only after complications develop, such as angina from coronary artery disease or neurologic symptoms from stroke. Rarely, inherited forms can produce visible findings like tendon xanthomas.<\/p>\n\n\n\n<p><strong>Q: What is the difference between LDL, HDL, and triglycerides?<\/strong><br\/>\nLDL (low-density lipoprotein) carries cholesterol to tissues and is commonly considered atherogenic when elevated. HDL (high-density lipoprotein) participates in reverse cholesterol transport, though its blood level does not fully represent its function. Triglycerides are a different type of lipid carried in triglyceride-rich lipoproteins and often track with insulin resistance and dietary factors.<\/p>\n\n\n\n<p><strong>Q: Do I need to fast for cholesterol testing?<\/strong><br\/>\nMany clinics use non-fasting lipid panels, but practices vary. Triglycerides are more affected by recent meals, which can influence calculated LDL-C in some settings. If results are unclear, clinicians may repeat testing under standardized conditions depending on local protocol.<\/p>\n\n\n\n<p><strong>Q: What causes Hypercholesterolemia besides diet?<\/strong><br\/>\nCauses include inherited conditions (such as familial hypercholesterolemia) and secondary contributors like hypothyroidism, kidney disease, cholestatic liver disease, and certain medications. Often, multiple factors combine, including genetics and lifestyle. Sorting out the cause usually relies on history, labs, and family patterns.<\/p>\n\n\n\n<p><strong>Q: How do clinicians decide how \u201cserious\u201d it is?<\/strong><br\/>\nThey interpret cholesterol levels alongside overall cardiovascular risk, including age, blood pressure, diabetes status, smoking, and any prior atherosclerotic events. A family history of premature cardiovascular disease and suspected familial hypercholesterolemia can raise concern even in younger people. The seriousness is therefore risk-context dependent rather than determined by a single number.<\/p>\n\n\n\n<p><strong>Q: If someone\u2019s cholesterol improves, does that remove cardiovascular risk?<\/strong><br\/>\nLowering atherogenic lipoprotein exposure is expected to reduce future risk, but it does not erase prior cumulative exposure or other risk factors. Blood pressure, glycemic control, smoking status, kidney disease, and inflammation still matter. Clinicians generally reassess risk over time rather than treating cholesterol as the only variable.<\/p>\n\n\n\n<p><strong>Q: What are typical next steps after Hypercholesterolemia is found?<\/strong><br\/>\nCommon next steps include repeating or confirming lipid testing if needed, evaluating for secondary causes, and assessing overall cardiovascular risk. Lifestyle factors and other comorbidities are reviewed because they influence management choices. Medication consideration depends on the clinical scenario and local guideline approach.<\/p>\n\n\n\n<p><strong>Q: How is follow-up usually monitored?<\/strong><br\/>\nFollow-up often includes periodic lipid panels and assessment of adherence, tolerability, and other cardiovascular risk factors. The timing and frequency vary by protocol and patient factors. Clinicians may also monitor for conditions that can shift lipid patterns over time, such as thyroid disease or changes in kidney function.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Hypercholesterolemia means a higher-than-desired level of cholesterol in the blood. It is a medical condition and a cardiovascular risk factor rather than a symptom. It is commonly identified on a lipid panel ordered in primary care and cardiology. In cardiology, it is closely linked to atherosclerotic cardiovascular disease risk assessment and prevention.<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-551","post","type-post","status-publish","format-standard","hentry"],"_links":{"self":[{"href":"https:\/\/heartcareforyou.in\/blog\/wp-json\/wp\/v2\/posts\/551","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/heartcareforyou.in\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/heartcareforyou.in\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/heartcareforyou.in\/blog\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/heartcareforyou.in\/blog\/wp-json\/wp\/v2\/comments?post=551"}],"version-history":[{"count":0,"href":"https:\/\/heartcareforyou.in\/blog\/wp-json\/wp\/v2\/posts\/551\/revisions"}],"wp:attachment":[{"href":"https:\/\/heartcareforyou.in\/blog\/wp-json\/wp\/v2\/media?parent=551"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/heartcareforyou.in\/blog\/wp-json\/wp\/v2\/categories?post=551"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/heartcareforyou.in\/blog\/wp-json\/wp\/v2\/tags?post=551"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}